{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:31Z","timestamp":1772120011628,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chongqing Natural Science Foundation Innovation Joint Development Fund","award":["CSTB2024NSCQ-LZX0099"],"award-info":[{"award-number":["CSTB2024NSCQ-LZX0099"]}]},{"name":"Science and Technology Research Project of Chongqing Municipal Education Commission","award":["KJQN202200462"],"award-info":[{"award-number":["KJQN202200462"]}]},{"name":"General Project of the Chongqing Natural Science Foundation","award":["CSTB2023NSCQ-MSX0587"],"award-info":[{"award-number":["CSTB2023NSCQ-MSX0587"]}]},{"name":"A Joint Key Project of Science and Health Commission of Chongqing Municipality","award":["2023ZDXM020"],"award-info":[{"award-number":["2023ZDXM020"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02908-w","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T05:46:36Z","timestamp":1753508796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of PELP1 on proliferation, metastasis and angiogenesis of epithelial ovarian cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Lele","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiyue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinglin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changjiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weifeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"issue":"3","key":"2908_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2908_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag CJ, Fagan PJ, Ferlay J, et al. Ovarian cancer today and tomorrow: a global assessment by world region and human development index using GLOBOCAN 2020. Int J Cancer. 2022;151(9):1535\u201341.","journal-title":"Int J Cancer"},{"issue":"12","key":"2908_CR3","doi-asserted-by":"publisher","first-page":"6702","DOI":"10.3390\/ijms23126702","volume":"23","author":"DC Stieg","year":"2022","unstructured":"Stieg DC, Wang Y, Liu LZ, et al. ROS and miRNA dysregulation in ovarian cancer development, angiogenesis and therapeutic resistance. Int J Mol Sci. 2022;23(12):6702.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2908_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/14656566.2022.2112030","volume":"24","author":"N Singh","year":"2023","unstructured":"Singh N, Jayraj AS, Sarkar A, et al. Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer. Expert Opin Pharmacother. 2023;24(1):49\u201364.","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"2908_CR5","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69(4):280\u2013304.","journal-title":"CA Cancer J Clin"},{"key":"2908_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.critrevonc.2019.08.002","volume":"143","author":"I Tsibulak","year":"2019","unstructured":"Tsibulak I, Zeimet AG, Marth C. Hopes and failures in front-line ovarian cancer therapy. Crit Rev Oncol Hematol. 2019;143:14\u20139.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"2908_CR7","first-page":"CD015048","volume":"9","author":"A Bryant","year":"2022","unstructured":"Bryant A, Hiu S, Kunonga PT, et al. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery. Cochrane Database Syst Rev. 2022;9(9):CD015048.","journal-title":"Cochrane Database Syst Rev"},{"key":"2908_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.cancergen.2024.06.002","volume":"286\u2013287","author":"D Sonkin","year":"2024","unstructured":"Sonkin D, Thomas A, Teicher BA. Cancer treatments: past, present, and future. Cancer Genet. 2024;286\u2013287:18\u201324.","journal-title":"Cancer Genet"},{"key":"2908_CR9","doi-asserted-by":"publisher","first-page":"804983","DOI":"10.3389\/fonc.2022.804983","volume":"12","author":"AH Abdel Sater","year":"2022","unstructured":"Abdel Sater AH, Bouferraa Y, Amhaz G, et al. From tumor cells to endothelium and gut microbiome: a complex interaction favoring the metastasis cascade. Front Oncol. 2022;12:804983.","journal-title":"Front Oncol"},{"key":"2908_CR10","doi-asserted-by":"publisher","first-page":"111240","DOI":"10.1016\/j.cellsig.2024.111240","volume":"120","author":"W Zhou","year":"2024","unstructured":"Zhou W, Zeng T, Chen J, et al. Aberrant angiogenic signaling pathways:Accomplices in ovarian cancer progression and treatment. Cell Signal. 2024;120:111240.","journal-title":"Cell Signal"},{"issue":"9","key":"2908_CR11","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","volume":"52","author":"WS Lee","year":"2020","unstructured":"Lee WS, Yang H, Chon HJ, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475\u201385.","journal-title":"Exp Mol Med"},{"key":"2908_CR12","doi-asserted-by":"publisher","first-page":"1035323","DOI":"10.3389\/fimmu.2022.1035323","volume":"13","author":"W Zheng","year":"2022","unstructured":"Zheng W, Qian C, Tang Y, et al. Manipulation of the crosstalk between tumor angiogenesis and immunosuppression in the tumor microenvironment: Insight into the combination therapy of anti-angiogenesis and immune checkpoint blockade. Front Immunol. 2022;13:1035323.","journal-title":"Front Immunol"},{"issue":"5","key":"2908_CR13","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"2908_CR14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.gene.2016.03.017","volume":"585","author":"GR Sareddy","year":"2016","unstructured":"Sareddy GR, Vadlamudi RK. PELP1: structure, biological function and clinical significance. Gene. 2016;585(1):128\u201334.","journal-title":"Gene"},{"issue":"12","key":"2908_CR15","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1158\/0008-5472.CAN-07-5698","volume":"68","author":"C Dimple","year":"2008","unstructured":"Dimple C, Nair SS, Rajhans R, et al. Role of PELP1\/MNAR signaling in ovarian tumorigenesis. Cancer Res. 2008;68(12):4902\u20139.","journal-title":"Cancer Res"},{"issue":"3","key":"2908_CR16","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/mc.23152","volume":"59","author":"Y Luo","year":"2020","unstructured":"Luo Y, Li M, Pratap UP, et al. PELP1 signaling contributes to medulloblastoma progression by regulating the NF-\u03baB pathway. Mol Carcinog. 2020;59(3):281\u201392.","journal-title":"Mol Carcinog"},{"issue":"2","key":"2908_CR17","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/cancers14020383","volume":"14","author":"J Zhu","year":"2022","unstructured":"Zhu J, Wang L, Liu F, et al. Targeting PELP1 attenuates angiogenesis and enhances chemotherapy efficiency in colorectal cancer. Cancers. 2022;14(2):383.","journal-title":"Cancers"},{"key":"2908_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biopha.2017.07.071","volume":"94","author":"Z Wu","year":"2017","unstructured":"Wu Z, Ou L, Wang C, et al. Icaritin induces MC3T3-E1 subclone14 cell differentiation through estrogen receptor-mediated ERK1\/2 and p38 signaling activation. Biomed Pharmacother. 2017;94:1\u20139.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"2908_CR19","doi-asserted-by":"publisher","first-page":"167844","DOI":"10.1016\/j.bbadis.2025.167844","volume":"1871","author":"H Liu","year":"2025","unstructured":"Liu H, Hamaia SW, Dobson L, et al. The voltage-gated sodium channel \u03b23 subunit modulates C6 glioma cell motility independently of channel activity. Biochim Biophys Acta Mol Basis Dis. 2025;1871(6):167844.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"2908_CR20","doi-asserted-by":"publisher","first-page":"1416794","DOI":"10.3389\/fmicb.2024.1416794","volume":"15","author":"L Ou","year":"2024","unstructured":"Ou L, Hao Y, Liu H, et al. Chebulinic acid isolated from aqueous extracts of Terminalia chebula Retz inhibits Helicobacter pylori infection by potential binding to Cag A protein and regulating adhesion. Front Microbiol. 2024;15:1416794.","journal-title":"Front Microbiol"},{"issue":"3","key":"2908_CR21","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020:globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"7","key":"2908_CR22","doi-asserted-by":"publisher","first-page":"100578","DOI":"10.1016\/j.mcpro.2023.100578","volume":"22","author":"L Qian","year":"2023","unstructured":"Qian L, Sun R, Xue Z. Mass spectrometry-based proteomics of epithelial ovarian cancers: a clinical perspective. Mol Cell Proteomics. 2023;22(7):100578.","journal-title":"Mol Cell Proteomics"},{"issue":"1","key":"2908_CR23","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13048-023-01196-0","volume":"16","author":"M Wang","year":"2023","unstructured":"Wang M, Zhang J, Wu Y. Tumor metabolism rewiring in epithelial ovarian cancer. J Ovarian Res. 2023;16(1):108.","journal-title":"J Ovarian Res"},{"issue":"20","key":"2908_CR24","doi-asserted-by":"publisher","first-page":"3830","DOI":"10.1158\/0008-5472.CAN-22-0698","volume":"82","author":"KA Altwegg","year":"2022","unstructured":"Altwegg KA, Viswanadhapalli S, Mann M, et al. A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer. Cancer Res. 2022;82(20):3830\u201344.","journal-title":"Cancer Res"},{"issue":"1","key":"2908_CR25","doi-asserted-by":"publisher","first-page":"6783","DOI":"10.1038\/s41467-022-34610-0","volume":"13","author":"J Gordon","year":"2022","unstructured":"Gordon J, Chapus FL, Viverette EG, et al. Cryo-EM reveals the architecture of the PELP1-WDR18 molecular scaffold. Nat Commun. 2022;13(1):6783.","journal-title":"Nat Commun"},{"issue":"8","key":"2908_CR26","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1158\/1078-0432.CCR-10-2718","volume":"17","author":"D Chakravarty","year":"2011","unstructured":"Chakravarty D, Roy SS, Babu CR, et al. Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res. 2011;17(8):2250\u20139.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2908_CR27","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5483\/BMBRep.2020.53.6.060","volume":"53","author":"D Lim","year":"2020","unstructured":"Lim D, Do Y, Kwon BS, et al. Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer. BMB Rep. 2020;53(6):291\u20138.","journal-title":"BMB Rep"},{"issue":"1-2","key":"2908_CR28","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","volume":"31","author":"S Masoumi Moghaddam","year":"2012","unstructured":"Masoumi Moghaddam S, Amini A, Morris DL, et al. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31(1\u20132):143\u201362.","journal-title":"Cancer Metastasis Rev"},{"key":"2908_CR29","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.tranon.2023.101665","volume":"32","author":"S Qiao","year":"2023","unstructured":"Qiao S, Hou Y, Han B, et al. Tregs are involved in VEGFA\/ VASH1-related angiogenesis pathway in ovarian cancer. Transl Oncol. 2023;32:101665.","journal-title":"Transl Oncol"},{"issue":"6","key":"2908_CR30","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.humpath.2005.03.016","volume":"36","author":"RK Vadlamudi","year":"2005","unstructured":"Vadlamudi RK, Balasenthil S, Sahin AA, et al. Novel estrogen receptor coactivator PELP1\/MNAR gene and ERbeta expression in salivary duct adenocarcinoma: potential therapeutic targets. Hum Pathol. 2005;36(6):670\u20135.","journal-title":"Hum Pathol"},{"issue":"1","key":"2908_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nrm1009","volume":"4","author":"R L\u00f6sel","year":"2003","unstructured":"L\u00f6sel R, Wehling M. Nongenomic actions of steroid hormones. Nat Rev Mol Cell Biol. 2003;4(1):46\u201356.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"2908_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1074\/jbc.M116.739847","volume":"292","author":"BJ Girard","year":"2017","unstructured":"Girard BJ, Knutson TP, Kuker B, McDowell L, Schwertfeger KL, Ostrander JH. Cytoplasmic localization of proline, glutamic acid, leucine-rich protein 1 (PELP1) Induces breast epithelial cell migration through up-regulation of inhibitor of \u03baB kinase \u03f5 and inflammatory cross-talk with macrophages. J Biol Chem. 2017;292(1):339\u201350.","journal-title":"J Biol Chem"},{"issue":"13","key":"2908_CR33","doi-asserted-by":"publisher","first-page":"5571","DOI":"10.1158\/0008-5472.CAN-04-4664","volume":"65","author":"B Manavathi","year":"2005","unstructured":"Manavathi B, Nair SS, Wang RA, et al. Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation. Cancer Res. 2005;65(13):5571\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"2908_CR34","doi-asserted-by":"publisher","first-page":"26393","DOI":"10.1038\/s41598-024-76763-6","volume":"14","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Lu Y, Zhu Y, et al. ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6\/PI3K\/Akt\/NF-\u03baB pathway via IL-33. Sci Rep. 2024;14(1):26393.","journal-title":"Sci Rep"},{"issue":"1","key":"2908_CR35","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/s12964-024-01550-9","volume":"22","author":"Z Yu","year":"2024","unstructured":"Yu Z, Zhang Q, Wei S, et al. CD146+CAFs promote progression of endometrial cancer by inducing angiogenesis and vasculogenic mimicry via IL-10\/JAK1\/STAT3 pathway. Cell Commun Signal. 2024;22(1):170.","journal-title":"Cell Commun Signal"},{"key":"2908_CR36","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cancergen.2023.12.002","volume":"280\u2013281","author":"H Ohyama","year":"2024","unstructured":"Ohyama H, Hirotsu Y, Amemiya K, et al. Development of a molecular barcode detection system for pancreaticobiliary malignancies and comparison with next-generation sequencing. Cancer Genet. 2024;280\u2013281:6\u201312.","journal-title":"Cancer Genet"},{"key":"2908_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cancergen.2023.12.003","volume":"282\u2013283","author":"T Gonzalez","year":"2024","unstructured":"Gonzalez T, Nie Q, Chaudhary LN, Basel D, Reddi HV. Methylation signatures as biomarkers for non-invasive early detection of breast cancer: a systematic review of the literature. Cancer Genet. 2024;282\u2013283:1\u20138.","journal-title":"Cancer Genet"},{"issue":"6","key":"2908_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/nrclinonc.2011.74","volume":"8","author":"JM Ebos","year":"2011","unstructured":"Ebos JM, Kerbel RS. Antiangiogenic therapy:impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol. 2011;8(6):316.","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"2908_CR39","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s10147-021-02018-3","volume":"26","author":"M Sekine","year":"2021","unstructured":"Sekine M, Enomoto T, Watanabe Y, et al. The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer. Int J Clin Oncol. 2021;26(11):2130.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2908_CR40","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1158\/1535-7163.MCT-09-0274","volume":"8","author":"A Rapisarda","year":"2009","unstructured":"Rapisarda A, Hollingshead M, Uranchimeg B, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther. 2009;8(7):1867\u201377.","journal-title":"Mol Cancer Ther"},{"key":"2908_CR41","doi-asserted-by":"publisher","first-page":"216940","DOI":"10.1016\/j.canlet.2024.216940","volume":"593","author":"C Huang","year":"2024","unstructured":"Huang C, Tan H, Wang J, et al. \u03b2-hydroxybutyrate restrains colitis-associated tumorigenesis by inhibiting HIF-1\u03b1-mediated angiogenesis. Cancer Lett. 2024;593:216940.","journal-title":"Cancer Lett"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02908-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02908-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02908-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T05:24:43Z","timestamp":1757309083000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02908-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":41,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["2908"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02908-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6225502\/v1","asserted-by":"object"}]},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"14 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}],"article-number":"379"}}